Abstract
Objectives
Ferumoxytol is an ultra-small superparamagnetic iron oxide (USPIO) agent that is taken up by splenic tissue. This study describes our initial institutional experience of ferumoxytol-enhanced MRI (feMRI) for differentiating intrapancreatic splenules (IPS) from other pancreatic lesions.
Methods
In this retrospective study, patients with computed tomographic imaging that identified small enhancing lesions in the tail of the pancreas subsequently underwent feMRI for further characterization. The feMRI protocol included T2-weighted (T2w) imaging with and without fat suppression (FS), R2* mapping, diffusion-weighted imaging (DWI), and T1-weighted (T1w) imaging with FS, prior to contrast injection. Immediately after slow intravenous infusion with 3 mg/kg body weight ferumoxytol, T1w was repeated. Delayed imaging with all sequences were obtained 24–72 h after ferumoxytol administration.
Results
Seven patients underwent feMRI. In two patients, the pancreatic lesions were presumed as pancreatic neuroendocrine tumor (PNET) from feMRI and in the remaining 5 IPS. One of the two patients with PNET was symptomatic for NET. In another symptomatic patient with pathologically proven duodenal NET and suspected PNET, the pancreatic lesion was proven to be an IPS on feMRI. IPS demonstrated strong negative enhancement in feMRI on T2w and increased R2* values consistent with splenic tissue, while the presumed PNETs did not enhance. T2w FS was helpful on the pre-contrast images to identify IPS, while R2* did on post-contrast images. Neither DWI nor T1w contributed to differentiating PNETs from IPS.
Conclusions
This study demonstrates the potential utility of feMRI as a helpful adjunct diagnostic tool for differentiating IPS from other pancreatic lesions. Further studies in larger patient cohorts are needed.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Splenules (also known as splenunculus, accessory or supernumerary spleens) are ectopic splenic tissue [1, 2]. They are considered a developmental normal variant and have a high prevalence, with up to 10–30% of individuals having between one to six splenules [1,2,3,4,5,6,7]. The radiological and pathological literature report that approximately 75% of splenules are located in the splenic hilum, 20% near or in the pancreatic tail, and 5% in other regions. Cases of splenules found in the pelvis, groin, gonads, kidneys, adrenal glands, gastrosplenic ligament, liver, gastric wall, intestinal wall, omentum, and mesentery, as well lungs have been reported [2, 4, 8,9,10,11,12,13,14,15].
Splenules are frequently found as incidental findings during imaging and may be difficult to differentiate from other lesions [16]. In particular, intrapancreatic splenules (IPS) can mimic pancreatic neuroendocrine tumors (PNETs) [17, 18]. Both IPS and PNETs are often well circumscribed, enhancing lesions when imaged after bolus injection of extracellular contrast agents using computed tomography (CT) or magnetic resonance imaging (MRI) [6, 16, 17, 19,20,21,22,23,24,25,26]. While IPS are benign and require no intervention, PNETs are an uncommon and heterogeneous group of endocrine tumors that have malignant potential [27]. While some PNETs are functional, i.e., present with symptoms related to inappropriate excretion of various active hormones (e.g., gastrin, insulin, etc.), the majority are asymptomatic and non-functional. Moreover, non-functional PNETs have a worse prognosis with overall 5-year survival rate of 30%, compared to 97% with functional PNETs [28]. Preoperative biopsy of pancreatic tumors has not been shown to rule out malignancy with adequate reliability [28, 29]. Therefore, the need for a reliable imaging modality to differentiate IPS and PNETs is important for prognostic and therapeutic purposes.
When a splenule is suspected, the current imaging method of choice is 99mTc labeled heat-damaged red blood cell scintigraphy (99mTc-HDRBC) [5, 18, 30]. Although highly specific, scintigraphy is limited by low spatial resolution compared to CT and MRI, leading to low accuracy for evaluating lesions smaller than 20 mm. Unfortunately, the majority of intrapancreatic splenules, are smaller than 20 mm ranging typically from 10 to 15 mm in diameter [1, 3, 8, 18].
An alternative approach of using ultra-small superparamagnetic iron oxide particles (USPIO) for imaging the mononuclear phagocyte system (MPS, formerly known as the reticuloendothelial system, or RES) has been proposed and investigated [11, 31,32,33,34,35,36]. Like 99mTc-HDBRC, the use of USPIO is based on the phagocytosis of particles by the MPS [37,38,39]. This approach has not been adopted clinically due to the lack of approval of USPIO contrast agents and withdrawal of some agents from the market [39,40,41].
In 2009, the US Food and Drug Administration (FDA) approved ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA, USA) to treat iron deficiency anemia in adults with chronic kidney disease (CKD) [42, 43]. Importantly, this agent has favorable MR imaging properties, and there has been growing off-label use of ferumoxytol by clinicians and researchers as an MR contrast agent for both positive contrast T1-weighted (T1w) and negative contrast T2-weighted (T2w) imaging [42]. Organs of the MPS, including the spleen, demonstrate strong negative enhancement in T2w MRI 24–72 h after the administration of ferumoxytol, while pancreatic tissue does not [42,43,44]. Based on the imaging properties of ferumoxytol, our institution has adopted the use of ferumoxytol for the characterization of small pancreatic tail masses.
The purpose of this retrospective study was to describe our institution’s experience with ferumoxytol-enhanced MRI (feMRI) for differentiating IPS from other types of pancreatic lesions.
Methods
Our institution began formally offering feMRI in October 2014 after implementing a routine clinical protocol. This IRB-approved, retrospective study reviewed all feMRI studies performed for characterization of enhancing lesions in the tail of the pancreas. Patient demographics and relevant clinical information were retrieved from the electronic medical record.
Imaging protocol for feMRI
MRI was performed on various 1.5 and 3.0 T clinical MRI systems using 8–32 channel phased array torso coils (GE Healthcare, Waukesha, WI) (Table 1). For each patient, an initial MRI (MR#1) and a delayed MRI (MR#2), obtained 24–72 h after intravenous (IV) administration of ferumoxytol were always performed on the same MRI system.
The feMRI was performed as follows: Pre-contrast MR #1 axial and coronal 2D T2w single shot fast spin echo (T2-SSFSE, TR 700–2600 ms, TE 80–250 ms, SL 2–4 mm slice), 2D axial T2-weighted fast spin echo with fat suppression (FS) (T2w-FSE FS, TR 2.4–15 s, TE 90–98 ms, 4–5 mm slice), axial 3D T1w spoiled gradient echo with FS (LAVA-Flex, TR 3.6–4 ms, TE 1.7–1.9 ms, 12–15° flip angle, 3–5 mm slice), 3D axial multi-echo chemical shift encoded MRI (CSE-MRI) (IDEAL IQ, TR 6.6–13.8 s, TE 1.7–1.9 ms, 3–7° flip, 3–7 mm slice, 6–8 echoes per TR) for fat-corrected complex R2* mapping, and 2D diffusion-weighted imaging (DWI, TR 13.3–21 s, TE 51–63 ms, 4–5 mm slice, b = 50 and 500 s/mm2). The number of slices for each of the above acquisitions were adjusted to cover the relevant anatomy of interest, based on prior imaging. All acquisitions were performed in a breath-hold (20 s or less), except T2w-FSE FS and DWI, which were performed using respiratory triggering.
A slow intravenous infusion of 3 mg/kg body weight ferumoxytol diluted fivefold with normal saline was administered over at least 15 min outside of the MRI system [45]. The patients remained under observation for side effects starting 5 min prior to and 30 min after infusion, in accordance with the FDA Drug Safety Communication [45, 46]. After injection, T1w imaging was repeated.
Delayed MR #2 was performed 24–72 h after ferumoxytol administration using the same protocol as MR #1. In all cases, MR #2 was performed on the same MRI system as MR #1.
Image analysis
Regions of interest (ROIs) were measured in corresponding areas of axial T2w-SSFSE in the liver, spleen, pancreas, intrapancreatic lesion (SItissue), and fat (SIfat) both in the MR #1 as well MR #2 using McKesson PACS (McKesson Radiology Station, Version 12.3, Richmond, BC, Canada). Circular ROIs were drawn as large as possible while conforming to anatomic boundaries and avoiding large vessels, bile ducts, etc.
To compensate for signal inhomogeneities caused by sensitivity issues of the coils, every SIfat was measured as close to the SItissue in the adjacent retroperitoneal adipose tissue as possible, and normalized signal intensity SInorm was calculated as follows:
Qualitative assessment of the relative signal intensity of the intrapancreatic lesion to the pancreas and spleen both before and after contrast administration was performed for the T1w and diffusion-weighted images.
Due to the low R2* values and consequently low contrast on the pre-contrast R2* mapping sequence it was difficult to reliably delineate the upper abdominal organs, and the IPS in particular. For this reason, only qualitative assessment of iron uptake before and after ferumoxytol administration was performed relative to the spleen.
Results
Between October 2014 and January 2020, 7 patients (6 men and 1 woman, age range 41–77 years) underwent feMRI as part of their clinical workup for an enhancing intrapancreatic tail lesion observed on prior imaging. No side effects due to the ferumoxytol administration were experienced by any patients in this study.
Clinical presentation
The clinical presentation of the 7 patients are summarized in Table 1. In 5 patients, the indication for feMRI was based on an incidental, hypervascular intrapancreatic tail lesion (average size 11 mm, size range 5–17 mm) of unknown etiology identified on a prior imaging study as follows: MRI to exclude malignancy in a possible kidney donor (n = 1); chest CT for thoracic outlet syndrome (n = 1); and abdominal CT (n = 4) for cystic liver lesions, left rib pain, and a right inguinal hernia. In one patient (pt. 6) clinical symptoms had raised suspicion of an insulinoma for which imaging was obtained. In another patient (pt. 7) a CT was obtained due to epigastric pain and a complex clinical picture concerning for glucagonoma.
Of the 5 asymptomatic patients, three patients (pts. 1, 3, 5) had no notable laboratory derangements, and imaging findings of the ferumoxytol MRI supported the diagnosis of IPS.
One patient (pt.2) had a mildly elevated chromogranin A (CgA) level of 111 ng/mL (normal 0–95 ng/mL), but also suffered from asthma and took a serotonin specific reuptake inhibitor, which are both factors that can lead to an elevation of CgA [47, 48]. An attempt to clarify the clinical picture with an endoscopic ultrasound and fine needle aspiration (EUS-FNA) of a pancreatic tail lesion yielded indeterminate results. In this case, the imaging findings of the feMRI strongly supported the diagnosis of an IPS.
A second asymptomatic patient (pt. 4) had a notably elevated CgA level of 1576 ng/ml demonstrated during the workup of an incidental lesion. The feMRI supported the diagnosis of a PNET. Due of the relatively small lesion size of 12 mm as well its stability in size in comparison to a CT obtained one year prior, a watchful waiting strategy was chosen. A follow-up CT 7 months after our feMRI did not demonstrate any lesion growth or any metastatic disease. Continued surveillance is planned.
One symptomatic patient (pt. 6) was admitted to our institution for altered mental status found to be the result of severe hypoglycemia. His workup included fasting insulin check during which he became symptomatically hypoglycemic within 6 h of fasting and was found to have an insulin level of 24 µIU/mL (normal 3–25 µIU/mL), and a proinsulin level of 10.6 µIU/mL (normal ≤ 8.0 µIU/mL). His clinical history revealed up to 15 recurrent hypoglycemic episodes over the prior year with visual changes, including blurry vision/diplopia and later dizziness, confusion, and aphasia. His labs revealed normal CgA (52 mg/ml) and cancer antigen (CA) 19–9 (5 U/mL, normal 0–37 U/mL) levels. Abdominal CT showed a well-delineated, contrast-enhancing, hyperdense, 13 mm lesion in the portal-venous phase. Based on this clinical presentation and the CT imaging findings, a functional PNET (insulinoma) was suspected [49]. The feMRI supported this diagnosis. The patient underwent distal pancreatectomy and splenectomy, and pathologic analysis of the lesion revealed a well-differentiated neuroendocrine tumor, Grade 1 (Ki-67 2.5%), measuring 15 mm, with lymphovascular invasion and metastasis to one of twenty-five lymph nodes (1/25) (pT1N1).
In another patient (pt. 7), an abdominal CT demonstrated a 17 mm enhancing lesion in the pancreatic tail, which was noted to be stable in size from previous imaging in 2013, and a newly detected enhancing 15 mm duodenal lesion. The patient’s family history was notable for a pulmonary neuroendocrine tumor. The patient had brittle diabetes and was found to have an elevated glucagon level of 359 ng/L (normal 0–95 ng/mL), which was concerning for the presence of a glucagonoma. The CgA level was also elevated to 915 ng/mL, although the patient was taking a daily proton pump inhibitor, which is known to elevate CgA levels. EUS-FNA of the duodenal lesion was performed, and pathology demonstrated a low- grade neuroendocrine tumor (KI-67 < 3%). Given the presence of the duodenal lesion the pancreatic tail lesion was suspicious of NET. 68 Ga-DOTA-TATE PET/CT showed intense focal uptake for both the duodenal and pancreatic tail lesion. There was uncertainty in a PNET diagnosis of the pancreatic tail lesion because of the negative follow-up. On feMRI, the imaging findings of the pancreatic tail lesion were most consistent with IPS.
Imaging findings on MRI
IPS characteristics on feMRI
In the five cases with a presumed diagnosis of IPS (pts. 1–3, 5,7) feMRI showed consistent imaging patterns. For all sequences and phase of contrast, all IPS followed identical imaging characteristics as the spleen. Specific behavior is described below.
On T2w-SSFSE in the pre-contrast MRI, all IPS were isointense or slightly hyperintense to the pancreas and isointense to the spleen (Fig. 1). In the delayed MRI 24–72 h after the ferumoxytol administration, all IPS were hypointense to the pancreas and demonstrated a similar strong negative enhancement as the spleen (Fig. 2). Due to the uptake of USPIO, R2* maps showed a uniform and identical increased R2* in the IPS, spleen and liver in the delayed MRI compared to the pre-contrast MRI (Fig. 3).
All IPS behaved similarly to the spleen in pre-contrast T2w-FSE FS and DWI. On the pre-contrast T2w-FSE FS, the IPS were easily recognized as a well-delineated lesion that were homogeneously hyperintense compared to the pancreas. All IPS showed restricted diffusion in DWI similar to the spleen (Fig. 3). In the delayed MRI, all IPS were strongly hypointense relative to the pancreas with T2w-FSE FS. On the delayed MRI, the lesions were not visible on DWI, due to the T2 shortening from ferumoxytol.
On pre-contrast T1w-SGRE FS, the IPS appeared isointense or moderately hypointense to the pancreas. Immediately after the administration of ferumoxytol, the IPS appeared hyperintense, while in the delayed MRI (MR#2), they appeared isointense to the spleen. Of note, one patient (pt. 1) received gadobenate dimeglumine and was subsequently administered ferumoxytol 24 h prior to obtaining delayed imaging. This case was not included into the qualitative post-contrast T1 analysis.
The enhancement pattern of all five presumed IPS were consistent with a diagnosis of an intrapancreatic splenule as described in the literature [11, 35, 38, 39]. In 2 cases (pts. 2 and 5), additional accessory spleens measuring 6 and 15 mm were found in the hilum of the spleen (Fig. 1).
PNET characteristics on feMRI
In the two cases of presumed (pt. 4) or confirmed (pt. 6) diagnosis of a PNET, the contrast characteristics of these pancreatic lesions differed substantially from the IPS cases. With T2w-SSFSE on the pre-contrast MRI the PNETs were hypointense to the pancreas and spleen (Fig. 4). While the signal intensity (SI) of the liver and spleen in delayed MRI was markedly decreased on T2w-SSFSE, the PNETs remained unaltered (Fig. 2). Consequently, the PNETs appeared slightly hyper- or isointense relative to the spleen and had stable hypointensity relative to the pancreas (Fig. 4). R2* maps demonstrated increasing values in the liver and spleen on the delayed MRI in comparison to the pre-contrast MRI, but this pattern was not observed for the two PNETs.
On T2w-FSE FS the two PNETs were isointense to the pancreas in the immediate post-contrast and delayed MRI without any signal intensity change following ferumoxytol administration. Interestingly, the behavior in the DWI of the two PNETs was different. In one case (pt. 4) the PNET showed a similar restricted diffusion as the spleen; in the other (pt. 6) the PNET did not.
In the pre-contrast T1w-SGRE FS the lesions appeared isointense to the pancreas, and after ferumoxytol administration, no enhancement of either lesion was observed immediately after the administration of ferumoxytol.
The ferumoxytol contrast enhancement of the two PNETs differed significantly from the contrast behavior for IPS described in the literature [11, 35, 38, 39]. Consequently, the most probable diagnosis was thought to be PNET, confirmed histologically in one lesion.
Discussion
In this work we have described our experience with feMRI for characterizing small pancreatic tail lesions, which was found to be helpful in distinguishing IPS from PNETs. All IPS cases demonstrated a consistent imaging pattern on feMRI that corresponded to the expected pharmacokinetics of ferumoxytol in the MPS, unlike lesions suspected to be PNETs.
The characterization of intrapancreatic tail lesions either IPS or PNET is essential for treatment planning. The primary goal is to identify all PNETs and avoid unnecessary surgical resection of IPS [24]. Clinical symptoms are uncommon with PNETs, and biomarkers and even biopsies are often unreliable [16, 47, 48, 50, 51]. Since PNETs can be very slow growing, follow-up imaging can also be of limited value to rule out potential malignancy [28]. Current CT and MRI cross-sectional imaging approaches using extracellular contrast agents do not allow reliable differentiation of these lesions [11, 22].
The current most specific imaging modality to differentiate IPS from PNETs, 99mTc-HDRBC, offers limited spatial resolution for lesions smaller than 20 mm and requires exposure to ionizing radiation [5, 18, 52]. 68 Ga-labeled somatostatin analogs (DOTA-TOC, DOTA-TATE, DOTA-NOC) for Positron Emission Tomography/Computed Tomography (PET/CT) has emerged as a reliable imaging modality for well-differentiated neuroendocrine tumors [53,54,55]. However, since splenic tissue also demonstrates high uptake of somatostatin analogs, this modality does not enable the differentiation of IPS from PNETs [56, 57]. Our clinical implementation of feMRI resulted in reliable distinction between IPS and PNETs. Additionally, all lesions we examined using feMRI were < 20 mm and were identified easily with the high spatial resolution of MRI.
As expected physiologically, all IPS demonstrated negative enhancement on delayed T2-weighted imaging after ferumoxytol administration in a manner consistent with splenic tissue. In contrast, the PNET cases did not demonstrate negative enhancement or follow the behavior of the spleen. Additionally, the liver and spleen demonstrated increasing R2* values after the administration of ferumoxytol, indicating the presence of iron uptake in the MPS. This corresponds with the known pharmacokinetics of USPIO by the MPS [11, 35, 36, 38, 39, 58]. The two PNET cases in our study showed variable behavior: one showed restrictive diffusion and one did not. This may be explained by variable tumor biology that can occur at different tumor stages [59, 60]. Thus, DWI alone may not enable the reliable differentiation of IPS from PNET, although further studies in larger numbers of patients would be needed to confirm this speculation [61,62,63].
Additionally, dynamic T1w imaging following ferumoxytol administration demonstrated strong positive enhancement for IPS, while PNETs did not show similar positive enhancement. Factors that may contribute to this phenomenon include varying microvascular density of the tumors, the long blood half-life of ferumoxytol (14–21 h), and the specific T1w sequence used [43, 64, 65].
In clinical scenarios where there is a need to characterize a pancreatic lesion suspicious for PNET vs IPS, we recommend a feMRI protocol comprising T2w without and with FS, R2* mapping before and 72 h after the administration of ferumoxytol.T2w-SSFSE without FS is helpful to confirm negative contrast enhancement of the lesion as well as give valuable anatomical information. The T2w-FSE with FS can help find all accessory spleens on the pre-contrast images. The use of delayed phase T2w imaging only, may prove inadequate because PNETs can appear hypointense on T2-weighted imaging prior to the administration of ferumoxytol, as observed in our experience and in previous work [66]. We found quantitative R2* mapping helpful because it facilitates the detection of splenules on delayed MRI. Quantitative R2* mapping on pre-contrast MRI is also helpful in the identification of preexisting iron overload which could limit the utility of feMRI. Given that ferumoxytol has a long blood pool phase, waiting for 24 h after the infusion to obtain delayed imaging, has proven sufficient in this study to identify negative enhancement [44]. In contrast, with 99mTC-HDRBC imaging can be performed as early as 30 to 60 min after the tracer injection [5, 34, 37, 42, 43, 58, 67,68,69].
Ferumoxytol also has a very good safety profile for both adults and pediatric patients with side effects demonstrated in 10–15% (most common: nausea, dizziness, and diarrhea) and severe side effects in up to 1%, similar to known rates with use of ionic iodinated contrast agents [42, 43, 45, 70, 71].
Ferumoxytol is generally more costly than gadolinium agents, but the price for the MRI scan at all is more expensive [45].
Our study had several limitations. First, it is retrospective in nature. Although this study is, to the best of our knowledge, the largest series reported in the literature, it includes a relatively small number of patients. Our study included all patients in our clinical experience over 5 years, reflecting the overall rarity of this clinical situation. Additionally, we do not have pathological correlation for all cases, which is due to our protocol being implemented clinically. Biopsies of small pancreatic tail lesions are known to be unreliable and are, therefore, infrequently obtained, and surgery was appropriately not performed for those cases with presumed IPS. While one PNET was removed surgically, the clinical team elected to follow a watchful waiting strategy for the second small PNET based on the small size, patient preference, and the fact that many PNETs never undergo malignant transformation. Lastly, we did not have direct comparison of feMRI with 99mTC HDRBC, since the lesions included in this study were considered too small for 99mTC-HDRBC.
In conclusion, we have demonstrated the feasibility of feMRI for the characterization of small pancreatic tail lesions in a clinical case series. With high spatial resolution and no ionizing radiation, ferumoxytol-enhanced MRI can be a valuable adjunct to, or a substitute for, scintigraphy and somatostatin analogs PET/CT and may satisfy an important unmet clinical need. Further evaluation of feMRI in larger cohorts of patients is needed to confirm our initial experience.
References
Varga I, Galfiova P, Adamkov M, et al (2009) Congenital anomalies of the spleen from an embryological point of view. Med Sci Monit Int Med J Exp Clin Res 15:RA269–276
Dodds WJ, Taylor AJ, Erickson SJ, et al (1990) Radiologic imaging of splenic anomalies. AJR Am J Roentgenol 155:805–810. https://doi.org/10.2214/ajr.155.4.2119113
Mortelé KJ, Mortelé B, Silverman SG (2004) CT Features of the Accessory Spleen. Am J Roentgenol 183:1653–1657. https://doi.org/10.2214/ajr.183.6.01831653
Freeman JL, Jafri SZ, Roberts JL, et al (1993) CT of congenital and acquired abnormalities of the spleen. RadioGraphics 13:597–610. https://doi.org/10.1148/radiographics.13.3.8316667
d’Amico A, Cofalik A, Przeorek C, et al (2012) Role of nuclear medicine imaging in differential diagnosis of accessory spleens in patients after splenectomy. Pol J Radiol 77:68–71
Harris GN, Kase DJ, Bradnock H, Mckinley MJ (1994) Accessory spleen causing a mass in the tail of the pancreas: MR imaging findings. Am J Roentgenol 163:1120–1121. https://doi.org/10.2214/ajr.163.5.7976887
Vikse J, Sanna B, Henry BM, et al (2017) The prevalence and morphometry of an accessory spleen: A meta-analysis and systematic review of 22,487 patients. Int J Surg 45:18–28. https://doi.org/10.1016/j.ijsu.2017.07.045
Gayer G, Zissin R, Apter S, et al (2001) CT findings in congenital anomalies of the spleen. Br J Radiol 74:767–772. https://doi.org/10.1259/bjr.74.884.740767
Davidson LA, Reid IN (1997) Intrahepatic splenic tissue. J Clin Pathol 50:532–533
Etcheverry R, Allamand JP, Guzmán G, Robinson MI (1989) [Ectopic or migrating spleen and supernumerary spleens: detection and identification with 99mTc, 51Cr and 113In radioisotopes]. Rev Med Chil 117:1403–1408
Kim SH, Lee JM, Han JK, et al (2008) Intrapancreatic Accessory Spleen: Findings on MR Imaging, CT, US and Scintigraphy, and the Pathologic Analysis. Korean J Radiol 9:162. https://doi.org/10.3348/kjr.2008.9.2.162
Ruiz-Tovar J, Ripalda E, Beni R, et al (2009) Hypersplenism caused by an accessory spleen mimicking an intra-abdominal neoplasm: report of a case. Surg Today 39:818–820. https://doi.org/10.1007/s00595-008-3919-z
Landry ML, Sarma DP (1989) Accessory spleen in the head of the pancreas. Hum Pathol 20:497
Hwang HS, Lee SS, Kim SC, et al (2011) Intrapancreatic accessory spleen: clinicopathologic analysis of 12 cases. Pancreas 40:956–965. https://doi.org/10.1097/MPA.0b013e318216815b
Rodrigue PD, Fakhri AA, Lim JT (2016) Scintigraphic Diagnosis of Intrathoracic Splenic Implants Masquerading as Malignancy. J Nucl Med Technol 44:267–268. https://doi.org/10.2967/jnmt.116.178616
Bhutiani N, Egger ME, Doughtie CA, et al (2017) Intrapancreatic accessory spleen (IPAS): A single-institution experience and review of the literature. Am J Surg 213:816–820. https://doi.org/10.1016/j.amjsurg.2016.11.030
Wcislak SM, Stiles ZE, Deneve JL, et al (2018) Hypervascular lesions of the pancreas: Think before you act. Am J Surg. https://doi.org/10.1016/j.amjsurg.2018.11.021
Kawamoto S, Johnson PT, Hall H, et al (2012) Intrapancreatic accessory spleen: CT appearance and differential diagnosis. Abdom Radiol 37:812–827. https://doi.org/10.1007/s00261-011-9830-x
Lin J, Jing X (2010) Fine-Needle Aspiration of Intrapancreatic Accessory Spleen, Mimic of Pancreatic Neoplasms. Arch Pathol Lab Med 134:5
Chan KJ, Fenton-Lee D (2018) Intrapancreatic Accessory Spleen Masquerading as a Pancreatic Neuroendocrine Tumor. J Gastrointest Surg 22:1799–1800. https://doi.org/10.1007/s11605-018-3701-5
Spencer LA, Spizarny DL, Williams TR (2010) Imaging features of intrapancreatic accessory spleen. Br J Radiol 83:668–673. https://doi.org/10.1259/bjr/20308976
Sothilingam N, Leedahl T, Kriegler S, et al (2011) Intrapancreatic accessory spleen: A case report and review of the literature. Int J Surg Case Rep 2:128–130. https://doi.org/10.1016/j.ijscr.2011.02.013
Touré L, Bédard J, Sawan B, Mosimann F (2010) Intrapancreatic accessory spleen mimicking a pancreatic endocrine tumour. Can J Surg 53:E1–E2
Hamada T, Isaji S, Mizuno S, et al (2004) Laparoscopic spleen-preserving pancreatic tail resection for an intrapancreatic accessory spleen mimicking a nonfunctioning endocrine tumor: report of a case. Surg Today 34:878–881. https://doi.org/10.1007/s00595-004-2839-9
Kurmann A, Michel J-M, Stauffer E, Egger B (2010) Intrapancreatic Accessory Spleen Misdiagnosed as a Nonsecreting Endocrine Tumor: Case Report and Review of the Literature. Case Rep Gastroenterol 4:210–214. https://doi.org/10.1159/000318857
George M, Evans T, Lambrianides AL (2012) Accessory spleen in pancreatic tail. J Surg Case Rep 2012:rjs004–rjs004. https://doi.org/10.1093/jscr/rjs004
Klöppel G (2017) Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med 33:324–330. https://doi.org/10.1159/000481390
Ehehalt F, Saeger HD, Schmidt CM, Grützmann R (2009) Neuroendocrine tumors of the pancreas. The Oncologist 14:456–467. https://doi.org/10.1634/theoncologist.2008-0259
Hartwig W, Schneider L, Diener MK, et al (2009) Preoperative tissue diagnosis for tumours of the pancreas. Br J Surg 96:5–20. https://doi.org/10.1002/bjs.6407
Pohlson EC, Wilkinson RW, Witzum KF, Coel MN (1994) Heat-damaged red cell scan for intraoperative localization of the accessory spleen. J Pediatr Surg 29:604–608
Weissleder R, Elizondo G, Wittenberg J, et al (1990) Ultrasmall superparamagnetic iron oxide: an intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175:494–498. https://doi.org/10.1148/radiology.175.2.2326475
Robertson F, Leander P, Ekberg O (2001) Radiology of the spleen. Eur Radiol 11:80–95. https://doi.org/10.1007/s003300000528
Stark DD, Weissleder R, Elizondo G, et al (1988) Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168:297–301. https://doi.org/10.1148/radiology.168.2.3393649
Ferrucci JT, Stark DD (1990) Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years. Am J Roentgenol 155:943–950. https://doi.org/10.2214/ajr.155.5.2120963
Boraschi P, Donati F, Volpi A, Campori G (2005) Intrapancreatic Accessory Spleen: Diagnosis with RES-Specific Contrast-Enhanced MRI. Am J Roentgenol 184:1712–1713. https://doi.org/10.2214/ajr.184.5.01841712
Herédia V, Altun E, Bilaj F, et al (2008) Gadolinium- and superparamagnetic-iron-oxide-enhanced MR findings of intrapancreatic accessory spleen in five patients. Magn Reson Imaging 26:1273–1278. https://doi.org/10.1016/j.mri.2008.02.008
Front D, Israel O, Groshar D, Weininger J (1984) Technetium-99m-labeled red blood cell imaging. Semin Nucl Med 14:226–250
Pouliquen D, Le Jeune JJ, Perdrisot R, et al (1991) Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 9:275–283
Kim SH, Lee JM, Han JK, et al (2006) MDCT and superparamagnetic iron oxide (SPIO)-enhanced MR findings of intrapancreatic accessory spleen in seven patients. Eur Radiol 16:1887–1897. https://doi.org/10.1007/s00330-006-0193-6
Wáng YXJ, Idée J-M (2017) A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging. Quant Imaging Med Surg 7:88–122. https://doi.org/10.21037/qims.2017.02.09
Wang Y-XJ (2015) Current status of superparamagnetic iron oxide contrast agents for liver magnetic resonance imaging. World J Gastroenterol 21:13400–13402. https://doi.org/10.3748/wjg.v21.i47.13400
Bashir MR, Bhatti L, Marin D, Nelson RC (2015) Emerging applications for ferumoxytol as a contrast agent in MRI. J Magn Reson Imaging 41:884–898. https://doi.org/10.1002/jmri.24691
Toth GB, Varallyay CG, Horvath A, et al (2017) Current and potential imaging applications of ferumoxytol for magnetic resonance imaging. Kidney Int 92:47–66. https://doi.org/10.1016/j.kint.2016.12.037
Wells S Pharmacokinetics of ferumoxytol in the abdomen and pelvis: A dosing study with 1.5T and 3.0T MRI relaxometry. Radiology
Vasanawala SS, Nguyen K-L, Hope MD, et al (2016) Safety and technique of ferumoxytol administration for MRI. Magn Reson Med 75:2107–2111. https://doi.org/10.1002/mrm.26151
Research C for DE and Drug Safety and Availability - FDA Drug Safety Communication: FDA strengthens warnings and changes prescribing instructions to decrease the risk of serious allergic reactions with anemia drug Feraheme (ferumoxytol). https://www.fda.gov/Drugs/DrugSafety/ucm440138.htm. Accessed 31 Oct 2018
Gut P, Czarnywojtek A, Fischbach J, et al (2016) Chromogranin A – unspecific neuroendocrine marker. Clinical utility and potential diagnostic pitfalls. Arch Med Sci AMS 12:1–9. https://doi.org/10.5114/aoms.2016.57577
Di Giacinto P, Rota F, Rizza L, et al (2018) Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors. Int J Endocrinol 2018:1–12. https://doi.org/10.1155/2018/8126087
Okabayashi T, Shima Y, Sumiyoshi T, et al (2013) Diagnosis and management of insulinoma. World J Gastroenterol WJG 19:829–837. https://doi.org/10.3748/wjg.v19.i6.829
Kruljac I, Vurnek I, Maasberg S, et al (2018) A score derived from routine biochemical parameters increases the diagnostic accuracy of chromogranin A in detecting patients with neuroendocrine neoplasms. Endocrine 60:395–406. https://doi.org/10.1007/s12020-018-1592-6
Öberg K (2012) Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics 67:109–112. https://doi.org/10.6061/clinics/2012(Sup01)18
Ota T, Tei M, Yoshioka A, et al (1997) Intrapancreatic accessory spleen diagnosed by technetium-99m heat-damaged red blood cell SPECT. J Nucl Med Off Publ Soc Nucl Med 38:494–495
Deroose CM, Hindie E, Kebebew E, et al (2016) Molecular Imaging of Gastroenteropancreatic Neuroendocrine Tumors: Current Status and Future Directions. J Nucl Med 57:1949–1956. https://doi.org/10.2967/jnumed.116.179234
Tolomeo A, Lopopolo G, Dimiccoli V, et al (2020) Impact of 68Ga-DOTATOC PET/CT in comparison to 111In-Octreotide SPECT/CT in management of neuro-endocrine tumors. Medicine (Baltimore) 99:. https://doi.org/10.1097/MD.0000000000019162
Crown A, Rocha FG, Raghu P, et al (2020) Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. J Surg Oncol 121:480–485. https://doi.org/10.1002/jso.25812
Kulkarni HR, Prasad V, Kaemmerer D, et al (2013) High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT. Recent Results Cancer Res Fortschritte Krebsforsch Progres Dans Rech Sur Cancer 194:373–378. https://doi.org/10.1007/978-3-642-27994-2_19
Lancellotti F, Sacco L, Cerasari S, et al (2019) Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review. World J Surg Oncol 17:. https://doi.org/10.1186/s12957-019-1660-2
Weinmann H-J, Ebert W, Misselwitz B, Schmitt-Willich H (2003) Tissue-specific MR contrast agents. Eur J Radiol 46:33–44. https://doi.org/10.1016/S0720-048X(02)00332-7
Wang Y, Chen ZE, Yaghmai V, et al (2011) Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging JMRI 33:1071–1079. https://doi.org/10.1002/jmri.22541
Lotfalizadeh E, Ronot M, Wagner M, et al (2017) Prediction of pancreatic neuroendocrine tumour grade with MR imaging features: added value of diffusion-weighted imaging. Eur Radiol 27:1748–1759. https://doi.org/10.1007/s00330-016-4539-4
Jang KM, Kim SH, Lee SJ, et al (2013) Differentiation of an Intrapancreatic Accessory Spleen from a Small (<3-cm) Solid Pancreatic Tumor: Value of Diffusion-weighted MR Imaging. Radiology 266:159–167. https://doi.org/10.1148/radiol.12112765
Kang B-K, Kim JH, Byun JH, et al (2014) Diffusion-weighted MRI: usefulness for differentiating intrapancreatic accessory spleen and small hypervascular neuroendocrine tumor of the pancreas. Acta Radiol 55:1157–1165. https://doi.org/10.1177/0284185113513760
Kartalis N, Lindholm TL, Aspelin P, et al (2009) Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol 19:1981–1990. https://doi.org/10.1007/s00330-009-1384-8
d’Assignies G, Couvelard A, Bahrami S, et al (2009) Pancreatic Endocrine Tumors: Tumor Blood Flow Assessed with Perfusion CT Reflects Angiogenesis and Correlates with Prognostic Factors 1. Radiology 250:407–416. https://doi.org/10.1148/radiol.2501080291
Rodallec M, Vilgrain V, Couvelard A, et al (2006) Endocrine Pancreatic Tumours and Helical CT: Contrast Enhancement Is Correlated with Microvascular Density, Histoprognostic Factors and Survival. Pancreatology 6:77–85. https://doi.org/10.1159/000090026
Harisinghani MG, Saksena MA, Hahn PF, et al (2006) Ferumoxtran-10-Enhanced MR Lymphangiography: Does Contrast-Enhanced Imaging Alone Suffice for Accurate Lymph Node Characterization? Am J Roentgenol 186:144–148. https://doi.org/10.2214/AJR.04.1287
Saokar A, Braschi M, Harisinghani M (2006) Lymphotrophic nanoparticle enhanced MR imaging (LNMRI) for lymph node imaging. Abdom Imaging 31:660–667. https://doi.org/10.1007/s00261-006-9006-2
Saksena M, Harisinghani M, Hahn P, et al (2006) Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers. AJR Am J Roentgenol 187:W582-8. https://doi.org/10.2214/AJR.05.0873
Feng Q, Liu Y, Huang J, et al (2018) Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings. Sci Rep 8:2082. https://doi.org/10.1038/s41598-018-19628-z
Muehe AM, Feng D, von Eyben R, et al (2016) Safety Report of Ferumoxytol for Magnetic Resonance Imaging in Children and Young Adults. Invest Radiol 51:221–227. https://doi.org/10.1097/RLI.0000000000000230
Nguyen K-L, Yoshida T, Kathuria-Prakash N, et al (2019) Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI. Radiology 293:554–564. https://doi.org/10.1148/radiol.2019190477
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Muehler, M.R., Rendell, V.R., Bergmann, L.L. et al. Ferumoxytol-enhanced MR imaging for differentiating intrapancreatic splenules from other tumors. Abdom Radiol 46, 2003–2013 (2021). https://doi.org/10.1007/s00261-020-02883-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-020-02883-y